Diabetes is the fifth leading cause of death in most developed countries. In spite of this, the drugs available in the market for treatment of diabetes are more expensive with side effect. Therefore, there is a high demand of cost-effective novel natural antidiabetic drug without any side effect. In our investigation, we studied in silico the mechanism of secondary metabolites isolated from S. persica which modify the enzyme action, their in vitro inhibitory activity of alpha amylase and the phyto-constituent analysis those are responsible for its activity. In silico study revealed that kaempferol from S. persica is a most effective metabolite which can bind, interact and modulate the activity of all enzymes with much higher binding affinity and lesser binding energy such as -4.58 kcal/mol for alpha amylase, -4.76 kcal/mol for beta glucosidase, -4.97 kcal/mol for glycogen synthase kinase, -4.3kcal/mol for glucokinase and -3.85 kcal/mol for alpha glucosidase. Aqueous extract of S. persica has a high ability with 72.39% inhibition value to inhibit the activity of alpha amylase and 376μg /ml IC50 value in comparison with standard drug which show 65.99% inhibition value. Total 15 compounds have been detected in TLC analysis in different solvent system and different extracts. Kaempferol might be one of them, which attribute to the anti-diabetic property. Further purification and characterization of kaempferol is required, which may prove a probable anti-diabetic drug
